Wall Street Raider

// mechanics · m&a

Hostile takeovers and poison pills, as a game mechanic.

In most games, "acquire company" is a button with a price on it. Here it is a contested process that the target, its other shareholders, a rival bidder, and a regulator can all break. This is how the takeover engine resolves a bid, step by step, and every way it can go wrong.

The bid is an offer, not a purchase

Pressing Launch tender offer does not buy a company. It publishes a price at which you will buy shares from anyone who chooses to sell, and then the register decides.

Three groups hold the other side. Retail float tenders on a probability curve driven by your premium over the undisturbed price — a thin premium gets a thin response. AI rivals each carry a reservation price derived from their own valuation of the target, and will not tender a share below it no matter how long the offer stays open; if your price sits under a large holder's reservation, that block simply never moves. Corporate holders — companies that own stakes in other companies — tender according to whether the proceeds beat what the stake contributes to their own book.

This is why an offer can stall at 38% and stay there. You are not fighting a timer. You are fighting a price.

The control bar is 51%, and it is a bar

Control is not a sliding scale of influence. Below 51% you are a large shareholder with a seat at the table and no ability to direct the company. At 51% you control it: you can appoint the board, set dividend and buyback policy, direct its trading desk, fold it into a holding structure, or strip it.

The squeeze-out to full ownership is a separate step gated behind that same bar. You cannot force out a minority you have not already outvoted.

The poison pill actually dilutes

A defended target does not just refuse your offer. Its board can adopt a shareholder rights plan — a poison pill — with a defined trigger threshold. Cross that threshold and the pill flips in: every holder except the acquirer receives the right to buy new shares at a discount.

The consequence is arithmetic, not flavour text. New shares are issued to everyone but you. Your percentage stake falls. The shares you already bought at a premium are now a smaller slice of a company with more shares outstanding, and the cost of getting back to your prior position has gone up.

1. You accumulate quietly. Stake climbs toward the pill trigger. Nothing happens yet — this is the only cheap phase of a hostile bid.
2. You cross the trigger. The pill flips in. Dilution lands on your stake specifically.
3. Your options narrow. Keep buying into a diluted register at a worse effective price, negotiate with the board to redeem the pill, or run a proxy fight to replace the board that adopted it.
4. The board changes or you walk. A won proxy fight gets you a board that will pull the pill. A lost one leaves you holding an expensive minority stake in a company that now knows you are coming.

Proxy fights: taking the board instead of the shares

When the pill makes buying control too expensive, the alternative is to change who decides. A proxy fight is a separate contest run on the existing register: you solicit votes, the incumbent board solicits against you, and the outcome turns on your stake, the composition of the rest of the register, and how badly the company has performed under current management.

Winning replaces the board. The new board can redeem the pill, which reopens the direct route. Losing costs you the campaign spend and puts the target on notice.

White knights and greenmail

A target under pressure can find a friendlier acquirer. The white knight is a rival bidder introduced by the defending board, and it changes the shape of the auction — you are no longer negotiating with a reluctant seller, you are in a competitive process against a bidder with its own reservation price and its own balance sheet.

Greenmail is the other exit. The target buys your accumulated block back, usually at a premium, to make you go away. It is a real profit and a real ending: you get paid, you keep no control, and the company you targeted is now more indebted for having bought you off. The buyback is subject to the same legal-capital limits as any other distribution, so a target without the capacity cannot greenmail you out.

The regulator can kill a funded deal

The practical implication is that a roll-up strategy has a ceiling per industry. Consolidating five of ten firms in one sector is a fundamentally different plan from consolidating one firm in each of five sectors, and only one of those survives contact with the monitor.

Every way a hostile bid fails

Failure	Cause	What it costs you
Offer stalls below control	Premium sits under the reservation price of a large holder	Capital tied up in a minority stake at an inflated basis
Pill flip-in	Crossed the trigger without redeeming the plan first	Direct dilution of your stake; higher cost to continue
Outbid by a white knight	Rival's reservation price exceeded your final offer	Campaign costs; your block gets cashed out at their price
Proxy fight lost	Register unconvinced, or incumbent performance defensible	Solicitation spend, no board change, pill stays
Antitrust block	Post-deal industry concentration over the threshold	Financing committed against a deal that cannot close
Won, then drowned	Debt raised to fund the bid exceeds what the combined entity can service	See leveraged buyouts — this is the common one

What is deliberately simplified

• No regulatory calendar. Real tender offers run on statutory minimum periods and filing windows. Here the sequence is faithful but compressed into simulated days.
• One pill type. Real defences include staggered boards, dual-class structures, and dead-hand provisions. The engine models the flip-in rights plan, which is the one whose consequences a player can actually feel.
• Rivals don't collude. AI bidders evaluate independently. There are no consortium bids.